To Attract VC Dollars in 2025, Biopharma Must Bring the Data: Pitchbook

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk, Pitchbook said in its 2025 outlook.

Scroll to Top